Moreover, serum SAA concentration was remarkably reduced by antirheumatic drugs in patients with RA, particularly by Tocilizumab, an inhibitor of potent SAA-inducing cytokine IL-6, correlating well with RA activity and treatment outcomes. This evidence concerns the gene IL6 and rheumatoid arthritis.